Markovic Milica, Ben-Shabat Shimon, Dahan Arik
Department of Clinical Pharmacology, School of Pharmacy, Faculty of Health Sciences, Ben-Gurion University of the Negev, Beer-Sheva 84105, Israel.
Pharmaceutics. 2020 Oct 29;12(11):1031. doi: 10.3390/pharmaceutics12111031.
Prodrugs are bioreversible, inactive drug derivatives, which have the ability to convert into a parent drug in the body. In the past, prodrugs were used as a last option; however, nowadays, prodrugs are considered already in the early stages of drug development. Optimal prodrug needs to have effective absorption, distribution, metabolism, and elimination (ADME) features to be chemically stable, to be selective towards the particular site in the body, and to have appropriate safety. Traditional prodrug approach aims to improve physicochemical/biopharmaceutical drug properties; modern prodrugs also include cellular and molecular parameters to accomplish desired drug effect and site-specificity. Here, we present recently investigated prodrugs, their pharmaceutical and clinical advantages, and challenges facing the overall prodrug development. Given examples illustrate that prodrugs can accomplish appropriate solubility, increase permeability, provide site-specific targeting (i.e., to organs, tissues, enzymes, or transporters), overcome rapid drug metabolism, decrease toxicity, or provide better patient compliance, all with the aim to provide optimal drug therapy and outcome. Overall, the prodrug approach is a powerful tool to decrease the time/costs of developing new drug entities and improve overall drug therapy.
前药是生物可逆的无活性药物衍生物,能够在体内转化为母体药物。过去,前药被用作最后的选择;然而如今,在前药研发的早期阶段就会考虑使用它们。理想的前药需要具备有效的吸收、分布、代谢和排泄(ADME)特性,具备化学稳定性,对体内特定部位具有选择性,并具备适当的安全性。传统的前药方法旨在改善药物的物理化学/生物药剂学性质;现代前药还包括细胞和分子参数,以实现预期的药物效果和位点特异性。在此,我们介绍近期研究的前药、它们的药学和临床优势以及前药整体研发面临的挑战。所举的例子表明,前药能够实现适当的溶解度、增加通透性、提供位点特异性靶向(即靶向器官、组织、酶或转运体)、克服药物的快速代谢、降低毒性或提高患者的顺应性,所有这些都是为了提供最佳的药物治疗和疗效。总体而言,前药方法是一种强大的工具,可减少新药实体研发的时间/成本并改善整体药物治疗。